Lumito AB (publ) (“Lumito” or the “Company”) today announces that the Company has been granted a patent in India relating to its technology for tissue analysis using upconverting nanoparticles. The patent has previously been granted in Europe and the United States and further strengthens Lumito’s international intellectual property protection.
The granted patent protects the technology that enables imaging of samples with very high sensitivity and precision using upconverting nanoparticles. The technology is used to visualise markers in tissue samples and bodily fluids and constitutes the core of Lumito’s product SCIZYS.
The patent approval in India strengthens Lumito’s position in a market characterised by a rapidly growing healthcare sector, alongside strong development within research and medical technology. Patent protection in India is considered strategically important, both from a long-term commercial perspective and for future partnerships and collaborations.
“The approval of our product patent in India represents an important step in building a strong and global patent portfolio around our technology. Together with previous approvals in Europe and the United States, this provides broader commercial protection and strengthens our position ahead of future collaborations and market expansion,” says Sanna Wallenborg, CEO of Lumito.